PhaseRx, Inc. (NASDAQ:PZRX) Posts Earnings Results, Misses Expectations By $0.09 EPS
PhaseRx, Inc. (NASDAQ:PZRX) issued its quarterly earnings results on Thursday. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.21) by $0.09, Bloomberg Earnings reports.
Shares of PhaseRx (NASDAQ:PZRX) traded down 0.4493% during mid-day trading on Friday, hitting $0.6869. The stock had a trading volume of 68,040 shares. The stock has a 50 day moving average price of $0.82 and a 200-day moving average price of $1.24. The company’s market cap is $8.03 million. PhaseRx has a 52-week low of $0.01 and a 52-week high of $3.98.
COPYRIGHT VIOLATION NOTICE: “PhaseRx, Inc. (NASDAQ:PZRX) Posts Earnings Results, Misses Expectations By $0.09 EPS” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/phaserx-inc-nasdaqpzrx-posts-earnings-results-misses-expectations-by-0-09-eps/1475482.html.
Separately, ValuEngine lowered PhaseRx from a “sell” rating to a “strong sell” rating in a research note on Friday, May 19th.
An institutional investor recently raised its position in PhaseRx stock. Vanguard Group Inc. boosted its position in PhaseRx, Inc. (NASDAQ:PZRX) by 4.0% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 142,182 shares of the company’s stock after buying an additional 5,500 shares during the period. Vanguard Group Inc. owned approximately 1.22% of PhaseRx worth $135,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 1.95% of the company’s stock.
PhaseRx Company Profile
PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood.
Receive News & Ratings for PhaseRx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseRx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.